OrganOx Supports the Oxford Transplant Foundation

OrganOx is pleased to announce support of a local and very relevant charity, the Oxford Transplant Foundation.  The mission of this charity is to further the science and practice of transplantation, and to provide support for education and training in transplantation, over and above that provided by the University of Oxford and National Health Service.  

Learn more about the foundation HERE. 

Craig Marshall joins OrganOx as CEO

OrganOx is pleased to announce the appointment of Craig Marshall as CEO of OrganOx with effect from 1 January 2017. Craig joins OrganOx from Siemens Magnet Technology in Eynsham where he was the Managing Director since 2010,  with a turnover in excess of £150m and employing over 400 people. Craig will take over as CEO from Dr Les Russell who is moving to the position of Chairman.


Craig commented

“I am delighted to be able to take up the role of CEO of OrganOx at such an exciting time as the company transitions to full commercial activities. We have an outstanding team which has developed the world leading product for liver preservation, the OrganOx metra which is transforming liver transplantation around the globe and saving more lives by enabling the transplantation of more organs. I look forward to leading OrganOx to even greater success in the future by ensuring our proprietary technology is adopted by transplant centres in Europe, America and beyond.”


New Chairman Dr Les Russell added

“On behalf of our company and investors, it is my pleasure to welcome Craig to the role of CEO. It is a tribute to the team and strength of the company that we are able to recruit such a talented and high calibre individual as Craig. During his time at Siemens, Craig led his business to become a role model for other design and manufacturing businesses, picking up the coveted Factory of the Year award in 2015. I look forward to working with Craig as we drive the company forward on its mission to improve the supply and quality of organs for transplantation worldwide.”

Les and Craig  2.jpeg

OrganOx announces the first US transplant using the metra and initiation of the US Pivotal Study

OrganOx is pleased to announce that the University of Wisconsin, led by Principal Investigator Dr Anthony D’Alessandro, has transplanted the first patients in OrganOx’s pivotal US clinical study using the metra®. This study, operating under an Investigational Device Exemption (IDE) from the FDA, involves the transplant of up to 266 donor livers and is intended to test the safety and effectiveness of the OrganOx metra for preserving human livers prior to liver transplantation against the current standard of static cold storage.


Dr Les Russell, CEO of OrganOx commented “I’m delighted that Dr D’Alessandro and the University of Wisconsin have transplanted the first livers in our major study. The University of Wisconsin has a long history in pioneering novel approaches in transplantation and indeed, UW solution remains the most widely used organ preservation solution after more than 20 years in use.”


The OrganOx metra is a fully automated and transportable device for ex-vivo normothermic perfusion of donor livers prior to transplantation. The metra is the result of 20 years of research and is based on the pioneering work of Professors Peter Friend and Constantin Coussios at the University of Oxford. The CE marked metra has been used to transplant more than 170 livers in 6 countries. The device was recently used in a pivotal European study (COPE, Consortium for Organ Preservation) funded by the European Union under Framework 7 and the full results of this study are expected to be released shortly.


The US study will involve up to 15 major liver transplant centres in the US and is funded by a grant from Innovate UK, under the Biomedical Catalyst Award.

University of Wisconsin Principal Investigator Dr Anthony D'Alessandro and the team with the  metra  device during the first transplant (photograph courtesy of David Sohl)  

University of Wisconsin Principal Investigator Dr Anthony D'Alessandro and the team with the metra device during the first transplant (photograph courtesy of David Sohl)  

UK feasibility study published in American Journal of Transplantation

The results of the UK dual centre (Queen Elizabeth Hospital, Birmingham and King's College Hospital, London) feasibility study of the OrganOx metra device have been published in the June 2016 edition of the American Journal of Transplantation. This is the first in man application of this technology, and has been featured on the front cover of the journal. 

Access to the article is here:

Read More